Payer insights for cell and gene therapies

Emma Medin, VP, Pricing & Market Access, shares three payer insights to help you price appropriately for your cell or gene therapy.

Maximizing your virtual investigator meeting results

Learn how Parexel brings the principles and energy from face-to-face investigator meetings to an interactive and engaging virtual environment.

CAR-T: A patient’s cell therapy success story

Clinical trials of (CAR) T-cell therapies can present unprecedented enrollment challenges. How can we encourage participation in these trials?

Parexel on the pulse

Parexel regulatory expert, Mark Birse, gives an update on BREXIT.

Impact of Real-World Evidence on Payers & Patients

Dr. Scott Gottlieb, Former Commissioner of the Food and Drug Administration speaks with Parexel’s Peyton Howell, Executive Vice President, Chief Commercial & Strategy Officer and Sy Pretorius, Executi

Real-World Evidence: The Feedback Loop

RWE experts Leanne Larson, Senior Vice President and Worldwide Head, Real-World Evidence and Access and Amy McKee, Vice President, Regulatory and Access dig deeper into the evolving role of RWE.

Three risk management strategies for expedited approvals

Three risk management strategies for drug developers who wish to take full advantage of expedited pathways to achieve reimbursable innovation for the benefit of patients.

FDA Quality Management Maturity Pilot Programs

Parexel’s Paul Bridges, SVP Regulatory & Access and Lynne Ensor, Head of Global Compliance outline the benefits for drug manufacturers in participating in two new FDA pilot programs. These include API

Parexel on the Pulse

Paul Bridges on the EU Clinical Trial Regulation (CTR)

Genomics & biomarkers: Answers in the blood

Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi

Patient registries: Defining the patient

Parexel’s Leanne Larson, Corporate VP and WW Head, Real-world Evidence speaks with Deborah Collyar, cancer survivor and President of Advocates in Research about the importance of Real-world Evidence (

Innovation: Today’s patients, tomorrow’s medicines.

Sy Pretorius, EVP and Chief Medical & Scientific Officer, Parexel and Gadi Saarony, CEO, Advarra discuss how industry-leading innovations help to reduce the time and cost of development, minimize the

Leveraging Real-World Evidence in a Rare Disease Oncology Drug Approval

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our experts leveraged Real-World Evidence and FDA/Regulatory expertise to develop and execute a Synthet

Parexel Patient Advisory Council: EU Meeting

Rare Diseases: Aligning Expertise

See how Parexel are bringing together regulatory and market access experts to help companies developing rare and orphan disease products. Learn more about our Regulatory & Access Consulting Group: htt

Parexel Biotech: The value of patient-centric approaches - escaping the clinic

Parexel’s Rosamund Round, Director, Patient Innovation Center and Amy McKee, Vice President, Regulatory Consulting Services sit down with Monica Theis, a breast cancer survivor and two-time clinical t

Parexel Biotech – designed with biotech’s unique way of working in mind

James Anthony, SVP, Global Head Biotech and Graciela Rácaro, SVP, Global Head, Biotech Operations, both from Parexel, discuss how Parexel Biotech has been built to meet customer and the patient needs

Parexel dares to do its part #WithHeart

Navigating Global Regulatory Submissions

Parexel® Regulatory Consulting Services

An overview of Parexel’s Regulatory Consulting services.